Red ink continues to flow at MBI

Article

Ultrasound contrast agent developer Molecular Biosystems remains beset by heavy losses, despite signs of increasing market interest in its Optison ultrasound contrast agent. MBI, which announced a restructuring plan in November to reduce its high

Ultrasound contrast agent developer Molecular Biosystems remains beset by heavy losses, despite signs of increasing market interest in its Optison ultrasound contrast agent. MBI, which announced a restructuring plan in November to reduce its high cash-burn rate (SCAN 11/25/98), reported a net loss of $11.9 million during its fiscal third quarter (end-December), compared with a net loss of $5.9 million in the same period in 1997. Revenues were $2.2 million, compared with $1.4 million last year. Optison sales totaled $509,000 during the quarter.

The news wasn't all negative, however. The San Diego firm reported a 37% increase in end-user demand for Optison, representing the fourth straight quarter of growing acceptance and demand for the agent, according to MBI. This increased demand has not benefited the firm's financial results, as inventories already sold to the distribution channel were sufficient to meet the demand, according to the firm. If these sales rates continue to hold up, the company expects to have the initial inventories of Optison shipped by the quarter ending in June.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.